摘要
Abstract
OBJECTIVE:To make a systematic review on the efficacy and safety of canagliflozin in the treatment of type 2 dia-betes,and to provide evidence-based reference for clinical treatment. METHODS:Retrieved from Cochrane Library,PubMed,EM-Base,CBM and Wanfang database,randomized controlled trials (RCT) of canagliflozin (test group) versus placebo (control group)in the treatment of type 2 diabetes were collected,and Meta-analysis was performed by using Rev Man 5.2 statistical soft-ware after extracting data and evaluating quality. RESULTS:A total of 7 RCTs were included,involving 2 188 patients. The results of Meta analysis indicated that glycosylated hemoglobin levels [WMD=-0.82,95%CI(-0.99,-0.65),P<0.001],the proportion of HbA1c<7%[RR=2.51,95%CI(1.98,3.19),P<0.001],fasting plasma glucose levels [WMD=-32.91,95%CI(-39.65,-26.17), P<0.001] in test group were significantly better than those of control group,the incidence of genital tract infections was significant-ly higher than control group [RR=3.76,95%CI(2.23,6.35),P<0.001];however,compared with control group,there was no sig-nificant difference in the incidence of hypoglycemia [RR=1.13,95%CI(0.40,3.20),P=0.81] and urinary tract infections[RR=1.19,95%CI(0.82,1.73),P=0.36]. CONCLUSIONS:Canagliflozin is safe and effective in the treatment of type 2 diabetes,and it needs to be noticed with genital tract infections during the clinical use. Due to the limitation of methodology,large-scale and poly-centric RCT are required for further validation of the conclusions.关键词
坎格列净/2型糖尿病/系统评价/疗效/安全性Key words
Canagliflozin/Type 2 diabetes/Systematic review/Efficacy/Safety分类
医药卫生
